A Phase I, Open-Label, Dose Escalation, Multi-Center Study of TPI 287 in Patients With Advanced Malignancies.
Phase of Trial: Phase I
Latest Information Update: 08 Jan 2014
At a glance
- Drugs TPI 287 (Primary)
- Indications Hodgkin's disease; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Cortice Biosciences
- 09 Jun 2009 Sponser and affiliate (Archer Biosciences) added as reported by ClinicalTrials.gov.
- 21 Jan 2008 The expected completion date for this trial is now 1 Jan 2008.
- 22 Aug 2005 New trial record.